戻る
TransThera Sciences (Nanjing), Inc. (02617.HK)価格
02617.HK 株価推移チャート
TRANSTHERA-B (02617.HK)
TransThera Sciences (Nanjing), Inc.
HK$95.5
-2.1%
$-2.04
休場: Jan 16, 16:00:00 HKT
主要データ
前終値
$95.25
始値
$97.55
当日レンジ
$93.5 - $103.8
52週レンジ
$20.2 - $679.5
取引高
2.5M
平均取引高
1.7M
1株当たり利益(TTM)
-0.66
配当利回り
--
時価総額
$29.1B
TRANSTHERA-Bとは何ですか？
TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
